Pharmaceuticals is the industry where MFN duty matters least
Pharmaceutical manufacturing — NAICS 3254 (Pharmaceutical and Medicine Manufacturing) — has the lowest tariff intensity of any major US industrial category, and that has been true for decades. The reason is the WTO Pharmaceutical Tariff Elimination Agreement, finalised during the Uruguay Round and progressively expanded through subsequent reviews, which committed signatory countries to zero MFN duties on a defined list of pharmaceutical active ingredients, finished dosage forms, and related medicinal preparations. The agreement covers thousands of HTS lines across Chapter 30 (pharmaceutical products) and many intermediate substances under Chapter 29 used in pharmaceutical synthesis. For the bulk of inbound pharmaceutical trade flow, the customs duty component is therefore zero.
The four primary product categories tracked here reflect the structural mix of the inbound pharmaceutical flow. Generic drugs cover the off-patent finished-dosage-form category drawing primarily from India for the largest single-country share. Pharmaceutical ingredients — active pharmaceutical ingredients (APIs) and excipients — draw heavily from China and India for the cost-driven intermediate-substance segment. Medical devices range from disposable supplies through capital equipment, drawing from Germany, Ireland, Switzerland, China, and Mexico. Medical supplies and PPE — gloves, gowns, masks, syringes — draw broadly with Malaysia, Thailand, and Vietnam dominating the disposable-supply segment.
The MFN-only profile and why no Section 232 attaches
For the strict pharmaceutical subset within NAICS 3254, the dominant tariff layer is the column-one general MFN rate, which is zero across the bulk of pharmaceutical finished-product subheadings and most pharmaceutical ingredient subheadings under the WTO agreement. The Section 232 perimeter does not extend to pharmaceuticals under any current proclamation. Section 301 List 1 does attach to certain Chinese-origin pharmaceutical intermediates and certain medical-device categories, but the Trump administration in 2018 deliberately excluded most finished-dosage-form drugs from the Section 301 list to avoid disrupting US drug supply during the escalation cycle. The exclusion of finished pharmaceuticals was reaffirmed in subsequent list modifications.
The structural exception to the otherwise-clean zero-MFN profile is in the medical-device and medical-supply subset, where Chapter 90 (optical, photographic, cinematographic, measuring, checking, medical instruments) and certain miscellaneous Chapter subheadings carry non-zero MFN rates. Surgical instruments, dental equipment, diagnostic imaging machinery, and laboratory analyzers fall under Chapter 90 with MFN rates ranging from zero to roughly four percent depending on the specific subheading. Sterile disposables, syringes, and certain PPE categories fall under different chapters with similarly modest MFN rates. The USITC HTS Online Reference Tool is the authoritative per-subheading rate source.
The API supply concentration question
Active pharmaceutical ingredient supply has been one of the most-discussed strategic-supply-chain questions of the past decade. India dominates the generic-drug finished-dosage-form market for the US, but the API precursor inputs that feed Indian generic manufacturing often originate in China. The cascade means that a finished-dosage US generic prescription with an Indian country-of-origin label may carry Chinese-origin API inputs further upstream in the supply chain. The customs entry treats the finished product at the Indian origin under the WTO zero-MFN framework, but any Section 301 layer on Chinese APIs attaches at the upstream-import stage if a US manufacturer is directly sourcing the API for domestic finished-product manufacture.
The 2020 to 2025 policy discussion around US API supply resilience has produced several legislative proposals, some manufacturing-incentive measures, and various regulatory studies through the FDA and the Department of Health and Human Services. The structural concentration has begun to shift slowly toward US, European, and non-Chinese Asian API capacity, but the timeline for meaningful diversification is measured in years rather than quarters. The Defense Production Act has been invoked in select cases to support domestic API capacity expansion for critical-list drug categories.
The medical-device tariff intersection
Medical devices occupy a more complex tariff position than finished drugs because the WTO Pharmaceutical Tariff Elimination Agreement covers only a defined list of medical preparations, not the broader medical-device universe. Capital medical equipment — MRI scanners, CT machines, surgical robotic systems — falls under Chapter 90 with modest MFN duties that nonetheless translate into material absolute-dollar amounts on multi-million-dollar machine purchases. German, Japanese, and US manufacturers dominate the capital-equipment segment with limited Chinese-origin share. Disposable medical supplies (Chapter 39 plastic articles, Chapter 56 wadding and felt for surgical applications, Chapter 90 syringes and catheters) carry low MFN rates with broader Asian-supplier concentration.
Section 301 List 1 attaches to certain Chinese-origin medical device subheadings, with the most consequential examples falling in disposable supplies and lower-end diagnostic equipment categories. The Section 301 attachment has driven measurable sourcing migration away from Chinese-origin medical disposables toward Malaysian, Thai, Vietnamese, and Mexican supply. The FDA premarket-notification requirements operate independently of the customs tariff and apply to all medical-device imports regardless of country of origin.
FDA regulatory overlap with customs entry
Pharmaceutical and medical-device imports face a regulatory layer that is more rigorous than any other sector covered on this site. The FDA administers premarket-approval and 510(k) clearance requirements for drugs and medical devices respectively, requires FDA establishment registration for any foreign facility manufacturing FDA-regulated products for the US market, and operates an extensive Import Trade Auxiliary Communications System for prior-notice filings on regulated shipments. A customs entry at the relevant HTS subheading clears the tariff side but does not affect the FDA review, which can refuse entry on product-safety grounds independent of the customs determination.
For pharmaceutical importers, the practical compliance workflow involves multi-layered filings: a customs entry under the relevant HTS subheading at the duty rate (zero for most pharmaceutical finished products, modest for medical devices), the FDA prior-notice filing for the product category, the FDA establishment-registration verification for the foreign manufacturer, and any applicable Drug Supply Chain Security Act transaction-history compliance for prescription drug supply chain integrity. The Department of Commerce-published Pharmaceutical Trade compliance guidance integrates the customs and FDA components for importer reference.
Section 122 surcharge exemptions on pharmaceutical imports
The February 2026 Section 122 ten-percent surcharge was implemented with an explicit carve-out for essential pharmaceutical and medical-supply categories. The exemption list published alongside the Section 122 proclamation covers finished pharmaceutical dosage forms, defined medical-supply categories, and certain critical-medicine APIs. The carve-out was driven by the political and policy concern over drug-pricing impact and drug-supply continuity during the post-enactment transition period. For exempt pharmaceutical categories, the effective customs cost remains the MFN baseline (zero for most) without any Section 122 layer.
For non-exempt medical-device categories — primarily capital equipment and certain non-essential disposables — the Section 122 surcharge attaches as a separate ten-percent layer on top of the modest MFN baseline. The combined effective rate remains low relative to most other industries on this site, but the absolute dollar amount on multi-million-dollar capital equipment purchases is material.
Drug Supply Chain Security Act and serialised tracking
The Drug Supply Chain Security Act (DSCSA) imposes serialised-tracking requirements on prescription drug supply chains in the US market. The framework requires manufacturers, repackagers, wholesalers, and dispensers to capture and exchange product-level transaction history for each prescription drug movement through the supply chain. For imported prescription drugs, the DSCSA compliance work begins at the foreign-manufacturer serialisation stage and propagates through the import process, the US wholesaler distribution, and ultimately the pharmacy or hospital dispenser. The customs entry side is separate from the DSCSA compliance side, but the practical importer-of-record workflow must coordinate both frameworks for any prescription drug shipment.
The DSCSA framework reached its final implementation phase in 2023, with full interoperable electronic-traceability requirements applying to all covered prescription drug movements. The compliance burden has driven additional consolidation in the US pharmaceutical wholesaler segment because the traceability infrastructure costs reward scale. For importers handling smaller-volume specialty drug shipments, the DSCSA compliance overhead per shipment can be material relative to the product margin, which has shifted some specialty-drug supply away from small-importer direct-distribution channels toward established wholesaler intermediaries. The customs tariff side is unaffected by these distribution decisions; only the DSCSA-compliance distribution structure is.
How to verify a specific pharmaceutical or medical-device rate
The verification path centres on the HTS chapter identification (Chapter 30 for finished pharmaceutical products; Chapter 29 for organic-chemical pharmaceutical intermediates; Chapter 90 for medical instruments and apparatus; relevant disposable-supply subheadings across Chapters 39, 56, and others). The column-one general MFN rate is the starting point — typically zero for finished pharmaceuticals under the WTO agreement coverage, modest for medical devices and supplies. Section 301 attachment for Chinese-origin medical devices and certain pharmaceutical intermediates is the next layer. Section 122 exemption-list verification is the final step. The USITC DataWeb tariff database cross-references the rate against actual customs collections by quarter. The BLS QCEW industry index for NAICS 3254 provides the establishment and employment baseline. The FDA registry of foreign establishments is the parallel regulatory-compliance reference. Pharmaceutical-importer compliance teams typically maintain integrated tracking systems that coordinate customs clearance, FDA pre-import notification, DSCSA serialised-tracking events, and any applicable Drug Enforcement Administration controlled-substance notification requirements across the multi-framework regulatory perimeter that governs prescription drug and medical device imports into the US market.
